Cyclacel Pharmaceuticals Inc [CYCC] stock is trading at $0.35, up 18.43%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CYCC shares have gain 16.52% over the last week, with a monthly amount glided 65.42%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On September 07, 2018, Ladenburg Thalmann initiated with a Buy rating. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $5 on October 16, 2015. Roth Capital initiated its recommendation with a Buy and recommended $7 as its price target on February 04, 2010. In a note dated August 12, 2008, Piper Jaffray initiated an Buy rating and provided a target price of $5 on this stock.
Cyclacel Pharmaceuticals Inc [CYCC] stock has fluctuated between $0.17 and $3.08 over the past year. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. Cyclacel Pharmaceuticals Inc [NASDAQ: CYCC] shares were valued at $0.35 at the most recent close of the market. An investor can expect a potential return of 185.71% based on the average CYCC price forecast.
Analyzing the CYCC fundamentals
Cyclacel Pharmaceuticals Inc [NASDAQ:CYCC] reported sales of 0.04M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -347.19%, Pretax Profit Margin comes in at -346.95%, and Net Profit Margin reading is -215.28%. To continue investigating profitability, this company’s Return on Assets is posted at -2.26, Equity is 8.51 and Total Capital is 6.87.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3148 points at the first support level, and at 0.2757 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3795, and for the 2nd resistance point, it is at 0.4051.
Ratios To Look Out For
For context, Cyclacel Pharmaceuticals Inc’s Current Ratio is 0.59. Further, the Quick Ratio stands at 0.59, while the Cash Ratio is 0.5. Considering the valuation of this stock, the price to sales ratio is 3373.75.
Transactions by insiders
Recent insider trading involved Lazar David E., Interim CEO, that happened on Feb 26 ’25 when 194.63 million shares were sold.
